Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer

被引:27
作者
Mustea, A. [1 ]
Pirvulescu, C. [1 ]
Koensgen, D. [1 ]
Braicu, E. I. [2 ]
Yuan, S. [3 ]
Sun, P.
Lichtenegger, W. [1 ]
Sehouli, J. [1 ]
机构
[1] Charite Univ Med Berlin, Dept Obstet & Gynecol, D-13353 Berlin, Germany
[2] Med Univ, Dept Obstet & Gynecol, Cluj Napoca, Romania
[3] Zhejiang Canc Hosp, Dept Gynecooncol, Hangzhou 310022, Zhejiang, Peoples R China
关键词
IL-1; cytokine; expression; ascites; survival; ovarian cancer;
D O I
10.1016/j.cyto.2008.01.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Cytokines play a major role in promoting the growth and metastatic spread of cancer cells. Interleukin-1 alpha and beta(IL-1) and IL-1 RA are known to be critically involved in carcinogenesis and in various solid tumors. There are limited data on expression of IL-1 alpha, 0 and RA in serum and ascites in patients with advanced ovarian cancer. Objectives of this study were to investigate the level of IL-1 alpha, IL-1 beta and IL-1 RA in serum and ascites from patients with ovarian cancer and their impact on the prognosis. Methods: Fifty-three women with ovarian cancer (OC) (33 patients with primary OC and 20 with relapsed OC) and 50 women with benign gynaecological diseases as a control group (CG) were enrolled onto this prospective study. IL-1 alpha, beta and RA levels were analyzed in serum and ascites by ELISA technique. Results: The median age was 55 years (range 19 - 80) in the ovarian cancer group and 40 years (range 15 - 89) in the controls. The distribution of histological type of ovarian cancer was as follows: serous-papillary 43 (81.1%), 4 (7.5%) mucinous, 3 (5.7%) endometroid and 3 (5.7%) clear cell carcinoma. The concentrations of IL-1 beta and RA in ascites or peritoneal fluid were significantly increased in patients with OC in comparison to the CG, for both cytokines (p < 0.0001); also the concentration of IL-1 RA in serum was increased in OC (p=0.003) vs. CG. An increased level of IL-1 beta in ascites correlated significantly with a poorer histopathological grading (p=0.038). IL-1 RA concentration in ascites was correlated with advanced FIGO stage (p=0.049) and the IL-1 RA serum level with ascites volume (<= 500 ml vs. > 500 ml) (p=0.046). Patients with IL-1 RA level in ascites lower than the cut off value of 695.6 pg/ml showed a significant better progression-free median survival (24.6 vs. 12.8 months, p = 0.008) and postoperative median overall survival (34.6 vs. 17 months, p=0.01) in comparison to patients with an IL-1 RA level in ascites higher than the cut off level. Additionally, a higher expression of IL- I P in serum (p=0.004) and ascites (p=0.05) reduced significantly the progression-free survival. In the multivariate analysis, expression of IL-1 RA in ascites was an independent prognostic factor for good progression-free and postoperative overall survival (HR, 0.39 95% CI, 0. 18 - 0.83, p=0.01, HR, 0.36 95% CL 0. 16 - 0.8, p=0.01). Conclusions: IL- I RA levels in ascites lower than the cut off value of 695.6 pg/ml are associated with a significant improvement in postoperative and progression-free survival. IL-1 RA shows a prognostic relevance in ovarian cancer. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 43 条
[1]  
Apte RN, 2000, ADV EXP MED BIOL, V479, P277
[2]   CYTOKINE-INDUCED TUMOR IMMUNOGENICITY - ENDOGENOUS INTERLEUKIN-1-ALPHA EXPRESSED BY FIBROSARCOMA CELLS CONFERS REDUCED TUMORIGENICITY [J].
APTE, RN ;
DOUVDEVANI, A ;
ZOLLER, M ;
WHITE, RM ;
DVORKIN, T ;
SHIMONI, N ;
FIMA, E ;
HACHAM, M ;
HULEIHEL, M ;
BENHARROCH, D ;
VORONOV, E ;
SEGAL, S .
IMMUNOLOGY LETTERS, 1993, 39 (01) :45-52
[3]  
AREND W P, 1990, Progress in Growth Factor Research, V2, P193, DOI 10.1016/0955-2235(90)90018-F
[4]   HOST-TUMOR INTERACTION IN OVARIAN-CANCER - SPONTANEOUS RELEASE OF TUMOR-NECROSIS-FACTOR AND INTERLEUKIN-1 INHIBITORS BY PURIFIED CELL-POPULATIONS FROM HUMAN OVARIAN-CARCINOMA IN-VITRO [J].
BURGER, RA ;
GROSEN, EA ;
IOLI, GR ;
VANEDEN, ME ;
BRIGHTBILL, HD ;
GATANAGA, M ;
DISAIA, PJ ;
GRANGER, GA ;
GATANAGA, T .
GYNECOLOGIC ONCOLOGY, 1994, 55 (02) :294-303
[5]   A cytokine profile of normal and malignant ovary [J].
Burke, F ;
Relf, M ;
Negus, R ;
Balkwill, F .
CYTOKINE, 1996, 8 (07) :578-585
[6]   Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis [J].
Campion, GV ;
Lebsack, ME ;
Lookabaugh, J ;
Gordon, G ;
Catalano, M ;
Borenstein, D ;
Caldwell, J ;
Cohen, SA ;
Cohen, SB ;
Fleischmann, R ;
Heller, MD ;
Howard, P ;
Jaffer, AM ;
Kaine, JL ;
Kitsis, E ;
Kopp, EJ ;
Moreland, LW ;
OHanlan, M ;
Prupas, M ;
Rosenberg, A ;
Rutstein, J ;
Sack, MR ;
Schiff, MH ;
Singleton, CM ;
Taborn, J ;
Tindall, E ;
Weaver, AL ;
Yocum, D .
ARTHRITIS AND RHEUMATISM, 1996, 39 (07) :1092-1101
[7]   Interleukin 1 alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells [J].
Castrilli, G ;
Tatone, D ;
Diodoro, MG ;
Rosini, S ;
Piantelli, M ;
Musiani, P .
BRITISH JOURNAL OF CANCER, 1997, 75 (06) :855-859
[8]  
Chen ZC, 2001, CANCER-AM CANCER SOC, V92, P3068, DOI 10.1002/1097-0142(20011215)92:12<3068::AID-CNCR10149>3.0.CO
[9]  
2-5
[10]   A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate [J].
Cohen, SB ;
Moreland, LW ;
Cush, JJ ;
Greenwald, MW ;
Block, S ;
Shergy, WJ ;
Hanrahan, PS ;
Khraishi, MM ;
Patel, A ;
Sun, G ;
Bear, MB .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (09) :1062-1068